Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents CHAPEL HILL, N.C., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results from in vitro studies that highlight the potential of delafloxacin, an investigational fluoroquinolone,...

Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that...

Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the closing of a $70 Million Series 3 equity financing.  Current investor, Vatera Healthcare Partners,...

Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) --  Melinta Therapeutics today announced the initiation of a Phase 3 trial of delafloxacin, a novel investigational fluoroquinolone, for the...